The promise of safer blood transfusions is now within arms length of fulfillment. Moving into implementation of the Phase II trial is both a significant corporate and clinical accomplishment. I trial were presented at the American Society of Hematology by the study's principal investigator, James AuBuchon, MD, of Dartmouth-Hitchcock Medical Center. The Company maintains development and commercialization partnerships with Pall Corporation, Amersham Pharmacia Biotech, Haemonetics, the American Red Cross, and Bayer. About Pall Corporation Pall is the acknowledged technology leader in the increasingly complex and demanding filtration industry and has been for more than 50 years.
Pall serves customers throughout the health care and industrial marketplace.
In addition to providing leading-edge products for transfusion medicine, Pall is a primary supplier to the biopharmaceuticals, semiconductor, and municipal drinking water industries, to name a few. Pall blood filters are used in all ten countries that have mandated universal leukocyte reduction and in the 13 countries, including the US, that are moving toward routine blood filtration. Pall is also involved in extensive research and development in many other areas of blood safety including devices designed for sensitive and early detection of bacterial contamination of platelets, considered to be one of the greatest transfusion risks today. The Company is headquartered in East Hills, New York and has operations in over 30 countries. Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.